vimarsana.com
Home
Live Updates
Alentis Therapeutics: Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis : comparemela.com
Alentis Therapeutics: Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis
Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing
Related Keywords
Switzerland ,
France ,
French ,
Luigi Manenti ,
Sariette Witte ,
Opatrick Wilson ,
Thomas Baumert ,
Steven Nathan ,
Program At Inova Fairfax Hospital ,
University Of Strasbourg ,
Drug Administration ,
French National Institute Of Health ,
Research Inserm ,
Orphan Drug ,
Idiopathic Pulmonary Fibrosis ,
Chief Medical Officer ,
Medical Director ,
Advanced Lung Disease ,
Transplant Program ,
Inova Fairfax ,
Alentis Therapeutics ,
French National Institute ,
Medical Research ,
Public Relations Gmbh ,
Patrick Wilson ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.